A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma

NCT07128693 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Sacituzumab Tirumotecan in combination with tislelizumab
DRUG: Sacituzumab Tirumotecan in combination with anlotinib

Sponsor

The First Affiliated Hospital of Zhengzhou University